Dr. Rasbach has extensive experience in clinical pharmacology, basic science, and healthcare equity research. Prior to joining Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm that invests across biotechnology, biopharmaceuticals, drug delivery, and medical devices. Earlier in his career he was an equity research analyst and Vice President at T. Rowe Price, where he managed pharmaceutical, specialty pharmaceutical and biotechnology investments. Prior to joining T. Rowe, Dr. Rasbach was an equity research associate and Vice President at Cowen and Company, where he covered global pharmaceutical equities.

Dr. Rasbach holds a PhD in Pharmaceutical and Biomedical Sciences as well as a PharmD from the Medical University of South Carolina; he completed his postdoctoral training in the laboratory of Bruce Spiegelman at the Harvard Medical School. He also holds an MBA from The Citadel and a BS in Biology from Denison University.

Mr. Samikoglu is a public and private investor, entrepreneur and a former investment banker. Prior to Biosplice, he was the Co-Founder, Portfolio Manager and a Partner of Greywolf Capital Management LP, a New York-based investment fund managing capital in different strategies. Prior to forming Greywolf, he was the Director of Research and a Portfolio Manager of Goldman Sachs’ Special Situations Investing Group. Mr. Samikoglu began his career at Goldman, Sachs & Co. where he spent nine years, both as a proprietary investor and as an investment banker.

Mr. Samikoglu received his MBA from Harvard Business School and his BA in Economics from Hamilton College.

Dr Finian Tan is a venture capitalist, entrepreneur, and the founder and current chairman of Vickers Venture Partners, an international venture capital firm with a presence in Singapore, Shanghai, New York, Hong Kong, Silicon Valley, and San Francisco. Before he started Vickers, Dr. Tan was Managing Director and head of the Credit Suisse First Boston’s (“CSFB”) group of banks in Singapore and Malaysia, a role he took on after leaving his position as the Founding Partner and Managing Director of Silicon Valley venture capital firm Draper Fisher Jurvetson ePlanet for Asia, where he made an early and probably his most famous investment in Chinese tech giant Baidu. Prior to this, in 1997, Dr. Tan served as Deputy Secretary of the Ministry of Trade and Industry for the Singapore Government.

Dr. Tan received his Doctor of Philosophy from Cambridge University on the Shell/Cambridge Scholarship. He received his B.Sc. Degree in Engineering from the University of Glasgow, where he also won all the academic awards available for the examinations, including an award for being the top student for his course, as well as the most distinguished graduate award.

Nathan Akhavan serves as an Associate Research Analyst for Eventide, and an Associate for Eventide’s private fund. Mr. Akhavan has research responsibilities for healthcare investments at Eventide.

Prior to joining Eventide, Mr. Akhavan worked at Gryphon Partners in New York, where he served as an Investment Analyst covering the sectors of healthcare, technology, and sustainability. Prior to Gryphon, he conducted research on pancreatic cancer and oncogenes at MD Anderson Cancer Center and Columbia University Medical Center.

Mr. Akhavan holds an MBA from New York University’s Stern School of Business and a BA with honors from Yeshiva University in Biology.

Chidozie Ugwumba serves as Managing Partner of SymBiosis, a venture capital firm focused on investments in biotherapeutics. At SymBiosis, Mr. Ugwumba leads sourcing, due diligence, and execution of investments, and serves as an advisor to SymBiosis’ portfolio companies. He has led numerous investments in therapeutics companies in the US and Europe, across disease areas including CNS, cardiac, dermatology, GI, infectious disease, and oncology, and across modalities such as precision medicine, and cell, gene, and regenerative therapy. Prior to SymBiosis, Mr. Ugwumba led the Direct and Impact Investment Group of WIT, LLC—an investment management entity affiliated with Walton Enterprises—and worked on the Private Credit and Infrastructure teams at Partners Group, a global private investment manager. Mr. Ugwumba earned an MBA from the Johnson Graduate School of Management at Cornell University, and a BA in Political Science from Amherst College.

Stephen Zachary is a Partner and Portfolio Manager at Sands Capital and serves on the Boards of various therapeutics, diagnostics, and life sciences tools companies. Stephen received his PhD in Neuroscience from Johns Hopkins School of Medicine, and received a BA in Philosophy from Washington & Lee University. He is a member of the Kauffman Fellowship (Class 23).

Elena Shirokaya serves as Principal at IH International Advisors (“IHIA”). IHIA is part of a foundation-owned investment group, Interogo Holding AG, and provides private equity investment advisory services for a global and cross-sector portfolio covering investments in private equity funds, co-investments and direct investments. Ms. Shirokaya joined IHIA in 2012 and is based in London since 2018. Ms. Shirokaya leads sourcing and evaluating of private equity fund investments and co-investments in Europe and Asia. She holds various positions at LP advisory boards as part of IHIA’s portfolio management function. Prior to IHIA, Ms. Shirokaya was with Altran, now Capgemini Engineering and the Boston Consulting Group. She received MSc in Advanced Financial Economics from KU Leuven and MSc in Microfinance from Solvay Brussels School of Economics & Management.

Dr Xinhong Lim is a venture capital investor and award-winning scientist. He joined Vickers Venture Partners in 2015 and is based in Silicon Valley. He has led investments into companies in the life sciences, medical device, AI and advanced materials sectors, and advises on fund strategy in these areas. He serves as a director on the boards of Emergex (synthetic T-cell vaccines) and RWDC Industries (sustainable biopolymers), and as an observer on the boards of Aardvark (metabolic and inflammatory disease therapeutics), Lumitron (extremely brilliant Compton X-ray light sources), Sisaf (silicon-stabilized lipid nanoparticles for RNA delivery) and Biosplice (RNA-splicing modulatory therapeutics). He is Chief Strategy Officer of RWDC.

Dr Lim received his Ph.D. in Developmental Biology from Stanford University under the tutelage of Breakthrough Prize winner Professor Roel Nusse, a pioneer of Wnt signaling biology, and obtained a Certificate in Innovation and Entrepreneurship from the Stanford Graduate School of Business. He received a B.S. in Biochemistry from the University of Wisconsin-Madison, where he graduated with Highest Distinction. Dr Lim is an Assistant Professor (Adjunct) at the Skin Research Institute of Singapore (SRIS) and NTU LKC School of Medicine. He has served as an invited speaker for many international professional and scientific conferences and has been the principal investigator for more than $15 million of research grants. Dr Lim’s work has been published and cited in the most prestigious scientific journals, including Nature and Science, as well as highlighted in the international press, including by CNN and BBC. He is the recipient of numerous awards, including the Singapore National Academy of Sciences Young Scientist Award and the Ten Outstanding Young Singaporeans Award (Medical Innovation).